Advertisement
Advertisement
KROS
Keros Therapeutics, Inc. Common Stock
12.07
USDSponsored
+0.43
+3.69%
May 08, 16:00 UTC -4
Closed
After-Market
12.06
-0.01
-0.08%
KROS Earnings Reports
Positive Surprise Ratio
KROS beat 14 of 24 last estimates.
58%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$655.72K
/-$1.32
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
-96.39%
/+73.68%
Keros Therapeutics, Inc. Common Stock earnings per share and revenue
On May 04, 2026, KROS reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -1.10 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 510.00 thousand, with a --% difference. The market reacted with a +1.91% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -1.32 USD, with revenue projected to reach 655.72 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Iovance Biotherapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.19
Surprise
-24.35%
Corvus Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-2.95%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
Ginkgo Bioworks Holdings, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.09
Actual
-$1.28
Surprise
-17.35%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Codexis, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+28.26%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
PTC Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.47
Actual
-$0.03
Surprise
+93.75%
Scholar Rock Holding Corporation Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.81
Actual
-$0.83
Surprise
-1.62%
FAQ
What were Keros Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Keros Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Keros Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 1.91%, changed from $11.49 before the earnings release to $11.71 the day after.
When is Keros Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Keros Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Keros Therapeutics, Inc. Common Stock is expected to report EPS of -$1.32 and revenue of $655.72K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement